NOVAVAX 96 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Novavax, Inc. – NVAX
NEW ORLEANS–(BUSINESS WIRE)–Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until January 11, 2022 to file lead plaintiff applications in a securities class action lawsuit against Novavax, Inc. (NasdaqGS: NVAX), if they purchased the Company’s securities between March 2, 2021 and October 19, 2021, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of Maryland.
What You May Do
If you purchased securities of Novavax and would like to discuss your legal rights and how this case might affect you and your right to recover for your economic loss, you may, without obligation or cost to you, contact KSF Managing Partner Lewis Kahn toll-free at 1-877-515-1850 or via email (firstname.lastname@example.org), or visit https://www.ksfcounsel.com/cases/nasdaqgs-nvax/ to learn more. If you wish to serve as a lead plaintiff in this class action by overseeing lead counsel with the goal of obtaining a fair and just resolution, you must request this position by application to the Court by January 11, 2022.
About the Lawsuit
Novavax and certain of its executives are charged with failing to disclose material information during the Class Period, violating federal securities laws.
On August 5, 2021, the Company disclosed another delay in filing the Emergency Use Authorization (“EUA”) for its COVID-19 vaccine product candidate, NVX-CoV2373, from the third quarter of 2021 to the fourth quarter of 2021. On this news, Novavax’s stock price fell $46.31 per share, or 19.61%, to close at $189.89 per share on August 6, 2021. Then, on October 19, 2021, Politico reported that anonymous sources stated that manufacturing issues could delay regulatory authorizations and approvals for NVX-CoV2373 until the end of 2022.
On this news, Novavax’s shares plummeted $23.69 per share, or 14.76%, to close at $136.86 per share on October 20, 2021.
The case is Sinnathurai v. Novavax, et al., 21-cv-02910.
About Kahn Swick & Foti, LLC
KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms. KSF serves a variety of clients – including public institutional investors, hedge funds, money managers and retail investors – in seeking recoveries for investment losses emanating from corporate fraud or malfeasance by publicly traded companies. KSF has offices in New York, California, Louisiana and New Jersey.
To learn more about KSF, you may visit www.ksfcounsel.com.
Kahn Swick & Foti, LLC
Lewis Kahn, Managing Partner